Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07–523LS in Newborn Infants Exposed to HIV-1
Journal of the Pediatric Infectious Diseases Society · 06.02.2025 · 14 (2)
DOI: 10.1093/jpids/piaf002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, online erschienen am 16.01.2025. Verfasst von Coleen K Cunningham und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California, Irvine, Orange, CA 92868, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Infectious Disease Transmission, Vertical, HIV Antibodies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, NICHD NIH HHS, Colorado Clinical and Translational Science Award.
Abstract (Originalsprache)
Background
Vertical HIV-1 transmission despite antiretroviral therapy may be mitigated by the use of long-acting, broadly neutralizing, monoclonal antibodies (bNAb) such as VRC07–523LS. The present study was designed to determine the safety and pharmacokinetics of VRC07–523LS.
Methods
VRC07–523LS, 80 mg/dose, was administered subcutaneously after birth to non-breastfed (cohort 1; N = 11, enrolled in USA) and breastfed (cohort 2; N = 11, enrolled in South Africa and Zimbabwe) infants exposed to HIV-1. Breastfed infants (cohort 2) received a second 100-mg dose at 12 weeks if still receiving breastmilk. All infants received antiretroviral prophylaxis in addition to VRC07–523LS. VRC07–523LS levels were compared to VRC01 levels, as determined previously in this study.
Results
Local reactions (all grade ≤ 2) occurred after dose 1 in 18% of infants in cohort 1 and after doses 1 and 2 in 100% of infants in cohort 2. The VRC07–523LS dose at birth (mean 26 mg/kg) achieved a mean ± SD plasma level of 222.3 ± 71.6 mcg/mL by 24 hours and 18.4 ± 7.2 mcg/mL at week 12, prior to dose 2. The pre-established target of ≥ 10 mcg/mL at week 12 was met in 94% of infants. The terminal half-life of VRC07–523LS was observed to be 39.2 ± 5.0 days. At week 4 and week 8, bNAb levels were significantly higher (P ≤ .002) after one dose of VRC07–523LS, compared to one dose of VRC01 (20 mg/kg). No infant included in the study acquired HIV-1.
Conclusions
VRC07–523LS was well tolerated with pharmacokinetics that support further studies of potent long-acting bNAbs together with antiretrovirals to prevent HIV-1 acquisition in infants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of California, Irvine, Orange, CA 92868, USA.
- Division of Infectious Diseases, Children's Hospital of Orange County, Orange, CA 92868, USA.
- Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
- Statistical and Data Management Center/ Frontier Science and Technology Research Foundation, Brookline, MA 02446, USA.
- Departments of Pediatrics and Pharmacy, UC San Diego Schools of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA 92093, USA.
- FHI 360, Durham, NC 27701, USA.
ORCID-Profile: Coleen K Cunningham, Dwight E Yin, Murli Purswani
Förderung
- National Institute of Allergy and Infectious Diseases
- NICHD NIH HHS
- Colorado Clinical and Translational Science Award
- International Maternal Pediatric Adolescent AIDS Clinical Trials Network
- NIAID NIH HHS
- NIMH NIH HHS
- NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Cunningham, C. K., McFarland, E. J., Muresan, P., Capparelli, E. V., Perlowski, C., Johnston, B., Bone, F., Purdue, L., Yin, D. E., Moye, J., Spiegel, H. M. L., Majji, S., Theron, G. B., Mujuru, H. A., Purswani, M., Alvarez, G., Deville, J. G., Chambers, C., Brown, E., …, & Gama, L. (2025). Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07–523LS in Newborn Infants Exposed to HIV-1. Journal of the Pediatric Infectious Diseases Society, 14(2). https://doi.org/10.1093/jpids/piaf002
Vancouver
Cunningham CK, McFarland EJ, Muresan P, Capparelli EV, Perlowski C, Johnston B, et al. Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07–523LS in Newborn Infants Exposed to HIV-1. Journal of the Pediatric Infectious Diseases Society. 2025;14(2). doi:10.1093/jpids/piaf002
BibTeX
@article{Cunningham2025,
author = {Cunningham, Coleen K and McFarland, Elizabeth J and Muresan, Petronella and Capparelli, Edmund V and Perlowski, Charlotte and Johnston, Benjamin and Bone, Frederic and Purdue, Lynette and Yin, Dwight E and Moye, Jack and Spiegel, Hans M L and Majji, Sai and Theron, Gerhard B and Mujuru, Hilda A and Purswani, Murli and Alvarez, Grace and Deville, Jaime G and Chambers, Carrie and Brown, Emily and Harding, Paul A and Tobin, Nicole H and Low, Kwang and Gama, Lucio},
title = {Safety, Tolerability, and Pharmacokinetics of Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC07–523LS in Newborn Infants Exposed to HIV-1},
journal = {Journal of the Pediatric Infectious Diseases Society},
year = {2025},
volume = {14},
number = {2},
doi = {10.1093/jpids/piaf002}
}
EUVIMED